Glutaminyl based DPIV inhibitors

Details Glutaminyl based DPIV inhibitors Glutaminyl based DPIV inhibitors

2005-09-20

2005-09-20

Lambkin, Deborah C. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S423000, C548S200000, C548S531000

Reexamination Certificate

active

06946480

ABSTRACT:
The present invention provides compounds of the formula:wherein X═CH2or S or pharmaceutical acceptable salts thereof useful for treating conditions mediated by DPIV or DPIV-like enzymes, such as arthritis, obesity, immune and autoimmune disorders, allograft transplantation, cancer, neuronal disorders and dermal diseases.

REFERENCES:
patent: 2961377 (1960-11-01), Shapiro et al.
patent: 3174901 (1965-03-01), Sterne
patent: 3879541 (1975-04-01), Kabbe et al.
patent: 3960949 (1976-06-01), Ahrens et al.
patent: 4028402 (1977-06-01), Fischer et al.
patent: 4935493 (1990-06-01), Bachovchin et al.
patent: 5433955 (1995-07-01), Bredehorst et al.
patent: 5462928 (1995-10-01), Bachovchin et al.
patent: 5512549 (1996-04-01), Chen et al.
patent: 5543396 (1996-08-01), Powers et al.
patent: 5614379 (1997-03-01), MacKellar
patent: 5624894 (1997-04-01), Bodor
patent: 5827898 (1998-10-01), Khandwala et al.
patent: 5939560 (1999-08-01), Jenkins et al.
patent: 6006753 (1999-12-01), Efendic
patent: 6201132 (2001-03-01), Jenkins et al.
patent: 6303661 (2001-10-01), Demuth et al.
patent: 6319893 (2001-11-01), Demuth et al.
patent: 6500804 (2002-12-01), Demuth et al.
patent: 6548481 (2003-04-01), Demuth et al.
patent: 25 42 598 (1976-04-01), None
patent: 296 075 (1991-11-01), None
patent: 196 16 486 (1997-10-01), None
patent: 299 09 210 (1999-09-01), None
patent: 198 26 972 (1999-12-01), None
patent: 0 658 568 (1995-06-01), None
patent: 0 708 179 (1996-04-01), None
patent: 0 995 440 (2000-04-01), None
patent: 2 085 665 (1971-12-01), None
patent: 2 696 740 (1994-04-01), None
patent: 04-288098 (1992-10-01), None
patent: 4334357 (1992-11-01), None
patent: WO 91/11457 (1991-08-01), None
patent: WO 91/16339 (1991-10-01), None
patent: WO 91/17767 (1991-11-01), None
patent: WO 93/08259 (1993-04-01), None
patent: WO 95/11689 (1995-05-01), None
patent: WO 95/15309 (1995-06-01), None
patent: WO 95/29691 (1995-11-01), None
patent: WO 97/40832 (1997-11-01), None
patent: WO 97/45117 (1997-12-01), None
patent: WO 98/19998 (1998-05-01), None
patent: WO 98/22494 (1998-05-01), None
patent: WO 99/46272 (1999-09-01), None
patent: WO 99/61431 (1999-12-01), None
patent: WO 99/62914 (1999-12-01), None
patent: WO 00/01849 (2000-01-01), None
patent: WO 00/10549 (2000-03-01), None
patent: WO 00/53171 (2000-09-01), None
patent: WO 01/34594 (2001-05-01), None
patent: WO 01/62266 (2001-08-01), None
patent: WO 01/74299 (2001-10-01), None
patent: WO 01/89569 (2001-11-01), None
patent: WO 01/97808 (2001-12-01), None
patent: WO 02/20825 (2002-03-01), None
Campbell, I.W.New Antidiabetic Drugs,ed. C.J. Bailey & P.R. Flatt, Smith-Gordon, “Sulphonylureas and metformin: efficacy and inadequacy”. 3:33-51 (1990).
The Merck Index, 11thEdition,An Encyclopedia of Chemicals, Drugs,and Biologicals, 1989, p. 934.
The Merck Index, 12thEdition,An Encyclopedia of Chemicals, Drugs,and Biologicals, 1996, p. 1014.
Martindale The Extra Pharmacopoeia,30thEdition, London Pharmaceutical Press, 1993, p. 1619, p. 36.
Chemical Abstracts,vol. 115. No. 15, Oct. 14, 1991 (Oct. 14, 1991) Columbus, Ohio, US; abstract No. 149947q. Schoen Ekkehard et al: “Dipeptidyl peptidase IV in the immune system. Effects of specific enzyme inhibitors on activity of dipeptidyl peptidase IV and proliferation of human lymphocytes”.
Chemical Abstracts,vol. 126, No. 2, Jan. 13, 1997 (Jan. 13, 1997) Columbus, Ohio, US; abstract No. 16161j, Stoeckel A. et al: “Competitive inhibition of proline specific enzymes by amino acid thioxopyrrolidides and thiazolidides”.
Chemical Abstracts,vol. 118, No. 25, Jun. 21, 1993 (Jun. 21, 1993) Columbus, Ohio, US; abstract No. 255342k, Hosoda, et al, “Preparation of N-(heterocyclic Carbonyl) Amino Acids and Analogs and Prolyl Endopeptidase Inhibitors”, Nov. 1992 (Nov. 20, 1992).
Arai et al., “Synthesis of prolyl endopeptidase inhibitors and evaluation of their structure-activity relationships : in vitro inhibition of prolyl endopeptidase from Canine Brain”Chemical and Pharmaceutical Bulletin.,Bd. 41, No. 9, 1993, pp. 1583-1588.
J. Lin et al.: “Inhibition of depeptidyl peptidase IV by fluorolefin-containing n-peptidyl-O-hydroxylamine peptidomimetics”Proceedings of the National Academy of Sciences of USA,vol. 95, Nov. 1998, pp. 14020-14024.
Korom, S., et al “Inhibition of CD26/dipeptidyl peptidase IV activity in vivo prolongs cardiac allograft survival in rat recipients”,Transplantation,vol. 63, 1495-1500 (Nov. 10 (1997).
Tanka, S., et al., “Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV”,Int. J. Immunopharmacol,vol. 19, No. 1 pp. 15-24, (1997).
Mentlein, R., et al., “Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV”.Regul. Pept.49, 133-144 (1993).
Wetzel, W., et al., “Effects of the CLIP fragment ACTH 20-24 on the duration of REM sleep episodes”.Neuropeptides,31, 41-45 (1997).
Amasheh, S., et al., “Electrophysiological analysis of the function of the mammalian renal peptide transporter expressed inXenopus Laevisoocytes”.J. Physiol.504, 169-174 (1997).
Durinx, C.; et al.; “Reference Values for Plasma Dipepidyl-Pepidase IV activity and their Association with Other Laboratory Parameters”.Clin Chem Lab Med 2001,Feb.; 39 (2) :155-9, 1 page.
Gossrau, R.; “Cytochemistry of Membrane Proteases”,Histochem J,1985, Jul.; 17 (7) :737-71, 1 page.
Hahn, T.; et al.; “Enzyme Histochemical Evidence for the Presence of Potential Blood Pressure Regulating Proteases in Cultured Villous Explants from Humans First Trimester Placentae”.Acta Histochem1993, Dec.,95 (2):185-92, 1 page.
Heymann, E. et al., “Has Dipeptidyl Peptidase IV an Effect on Blood Pressure and Coagulation.”Klin Wochenschr,1984, Jan., 2;62 (1) :2-10, 1 page.
Magyar, C.E. et al., “Proximal Tubule Na Transporter Responses are the same during Acute and Chronic Hypertension.”Am J. Physiol Renal Physiol,2000, Aug.; 279 (2) :F358-69, 1 page.
Papies, B. et al., “Isoenzyme (Lactate Dehydrogenase, Asparatate Aminotransferase) and Dipeptidyl Peptidase IV Activity Changes in Blood Plasma Likely Indicative of Organ Involvement due to Arterial Hypertension.”Cor Vasa,1991; 33(3) :218-26, 1 page.
Qureshi. N.U.; et al., “Endogenous Neuropeptide Y Mediates Vasoconstriction during Endotoxic and Hemorrhagic Shock”.Regul Pept,1998, Sep. 25; 75-76:215-20, 1 page.
Index Nominum,International Drug Directory 1992/1993,Medpharm Scientific Publishers, pp. 728-729.
The Merck Index,An Encyclopedia of Chemicals and Drugs,9thEdition, Merck & Co., Inc., 1976, p. 773.
Willms et al.,Journal of Clinical Endocrinology Metabolism,“Gastric Emptying, Glucose Responses, and Insulin Secretion after a Liquid Test Meal: Effects of Exogenous Glucagon-Like Peptide-1 (GLP-1)-(7-36) Amide in Type 2 (Noninsulin-Dependent) Diabetic Patients”, 1996, 81(1):327-332.
Hoffmann et al.,Journal of Chromatography A,“Inhibition of dipeptidyl peptidase IV (DP IV) by anti-DP IV antibodies and non-substrate X-X-Pro- oligopeptides ascertained by capillary eletrophoresis”, 1995, 716:355-362.
C.B. Welch,Medical Management of Non-Insulin-Dependent(Type II)Diabetes,3rdedition, American Diabetes Association, “Diagnosis and Classification” p. 3, 1994, Pharmacologic Intervention (2 pages).
Mannucci et al.,Diabetes Care,“Effect of Metformin on Glucagon-Like Peptide 1 (GLP-1) and Leptin Levels in Obese Nondiabetic Subjects”, 24(3): 489-494, Mar. 2001.
Stryer,Biochemistry 3rdEd.,“Protein Conformation, Dynamics, and Fucntion”, 1988, p 191-193.
Pauly et al.,Regulatory Peptides,“Abstracts Issue: Abstracts from the 11thInternational Symposium on Regulatory Peptides”, Jul. 15, 1996, 64(1-3): 148 plus cover.
Gutniak et al.,New England Journal of Medicine,“Antidiabetogenic Effect of Glucagon-like peptide-1 (7-36) Amide in Normal Subjects and Patients With Diabetes Mellitus&#

Affiliated with

Also associated with

Rating

Glutaminyl based DPIV inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Glutaminyl based DPIV inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Glutaminyl based DPIV inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3389642